Covance, a contract research organization, is one company that is proving the prediction that pharmaceutical companies are starting to rely on them more heavily. This article mentions that profits have risen for the Covance by 22.7%. The contract research organization industry is one of the few that is experiencing growth in an otherwise dismal economy. As mentioned in our previous blog post, much of this is because the cost of in house procedures is much more expensive than that of outsourcing to companies such as Covance. The company is also very optimistic in its outlook, which is inline with the trend, and predicts that they will be able to post a 20% growth in profit by the end of 2008.
Search This Blog
Blog Archive
-
▼
2008
(97)
-
▼
August
(20)
- Oncology accounts for most clinical trials
- Chiltrem Early Phase has been fully integrated
- Covance Signs New Deal with Eli Lilly & CO
- Finding patients is the lengthy part of a clinical...
- AmeriStart to Promote Factory CRO
- New Investigations in Deaths of Babies in Clinical...
- Acurian Invests in better patient recruitment tech...
- ACRO Accepts New Members
- Accenture has Big Plans For Outsourcing Services
- BioMS Will Give $10m to MS Drug Testing
- Parexel and ClinPhone
- Encorium Group Announces $3.5 Million of New Contr...
- New Reports proposed by the FDA to monitor safety
- Eli Lilly and Co. To Sell Greenfield Laboratories
- India’s Clinical Trials
- Costs Are Too Much for a Drug Trial Center in Indi...
- Days for patients in clinical trials increasing
- Growth of CRO’s
- OCT Opens Office in New Markets
- Clinical Testing Company Seeing Rise in Profits
-
▼
August
(20)
No comments:
Post a Comment